Exciting development is to develop opportunities for umbilical cord stem cells, in accordance with article, published in November 2009, the opinion of an expert in biological therapy. This article discusses the development of carlecortemcel-l (brand of StemEx), strains of umbilical cord blood stem cells created by encouraging the proliferation of stem cells – without allowing to distinguish.
What does this mean and why is it important?
Although there is much evidence of the healing potential of stem cells extracted from the umbilical cord blood, it was claimed that a limited number of stem cells available from one unit of the banked is not sufficient for the treatment of patients other than children or adults is very small. Creating a method of multiplying these stem cells in their vital State of a pre-differentiated, researchers may potentially face this challenge and widen the application of multiple stem cell treatments.
The results of the phase I study carlecortemcel-l performed at the University of Texas m. d. Anderson Cancer Center reported in the article, suggest that the surcharges these stem cells enlarged umbilical cord is safe – and may be beneficial for adults and adolescents with leukemia and Lymphoma. The continuation phase II/III safety and efficacy studies named Are now registering youth and adults with a high risk of hematologic malignancies in clinical trials in the United States, Italy, Spain, Hungary and Israel. Gamida cell and Teva Pharmaceuticals, co-developers StemEx, predict the product officially reaching cabinets 2011.
Be the first to like this post.Tags: stem cellsThis entry was posted on 15 October 2009 at 12: 00 pm and is filed under the cord blood research. You can track any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback your own site.